Page 2 - Cyrus Karkaria News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cyrus karkaria. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cyrus Karkaria Today - Breaking & Trending Today

The Appeal of Single-use Tech

Single-use technology is the new norm in the pharma manufacturing process due to an array of benefits. The availability of this technology has made new biopharmaceutical companies adopt single-use systems, as it requires less upfront capital investment and enables quick advancement of development efforts towards new products. Having an upper hand, the single-use technology is vouched to be a game changer in the entire manufacturing process. ....

United States , Sachin Joshi , Stephenk Tingley , Ganesh Reddy , Ramit Chopra , Sanjiv Das , Suresh Beri , Raheel Shah , Biocon Biologics , Cyrus Karkaria , Bioprocess International , Thermo Fisher , Serum Institute Of India , Polysaccharide Conjugate Vaccine Division , Vice President , Serum Institute , Single Run , Global Manufacturing Head , Fisher Scientific , Thermo Scientific Dynaspin Single Use Centrifuge , Hyperforma Dynadrive Single Use , Single Use Technology , South Asia , Additional Director ,

Lupin gets Health Canada nod for plaque psoriasis treatment Rymti

Mumbai: Global pharma major, Lupin Limited, announced today that Health Canada has approved Rymti, its biosimilar to Enbrel (etanercept), for use in Canada.Rymti is indicated in the treatment of. ....

Cyrus Karkaria , Health Canada , Lupin Limited , Tumour Necrosis Factor , Sofia Mumtaz , Lupin News , Rheumatoid Arthritis , Juvenile Idiopathic Arthritis , Psoriatic Arthritis , Axial Spondyloarthritis , Plaque Psoriasis , Paediatric Plaque Psoriasis , Dr Cyrus Karkaria , Dr Sofia Mumtaz ,

We are pleased to partner with Irom in Japan to bring this important biosimilar to the market. Biosimilars are a key growth driver for Lupin, and through products such as this, we are making significant progress in improving access and affordability of im

It can result in severe clinical consequences, such as back pain and bone fractures particularly in the spine and hips,” said Dr. Cyrus Karkaria, President – Biotechnology, Lupin. ....

South Africa , Asia Pacific , Cyrus Karkaria , Biotechnology Pharmaceuticals , Irom Group , Latin America , Middle East , Great Place , Brand Promise , I Rom Group , Back Pain , Medical Technology , Pharmaceutical Industry , Pharmaceuticals Policy , Generic Drug , Pharmaceutical Industry In China , Pharmaceutical Industry In India ,

Lupin and I'rom inks agreement for Denosumab biosimilar for Japan

Denosumab is indicated for the treatment of postmenopausal women with osteoporosis. ....

Cyrus Karkaria , Ltd Irom , Lupin Ltd , Japan Irom Group Co , Lupin Limited , I Rom Group ,

Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan

Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumors among other indications.

....

South Africa , Asia Pacific , Cyrus Karkaria , Nilesh Gupta , Irom Group Co , Ltd Irom , Devices Agency , Lupin Limited , I Rom Group , Medical Devices Agency , Managing Director , Latin America , Middle East , Twin Tower , Clinical Trials ,